- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sanofi Pasteur Announces It Will Discontinue Its Bladder Cancer Vaccine
Sanofi Pasteur has announced that it has decided to discontinue production of the BCG vaccine, which is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder.
The hints were there when news trickled of a shortage of the BCG (bacille Calmette-Guerin) live intravesical (TheraCys Intravesical Injection) in September this year. Now, Sanofi Pasteur, the manufacturer of this vaccine—which is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder—has announced that it has decided to discontinue its production.
The news of a drug shortage of the vaccine was announced by the American Society of Health-System Pharmacists a couple of months back. In a letter announcing the decision, Sanofi says that the company did try to restore production to maintain long-term availability of the product, but the efforts fell short. The letter states that production at the drug manufacturing facility in Canada will halt by mid-2017. Anticipating this issue, Sanofi initiated a formal global process to find another company to take up manufacturing and commercialization of BCG, without success.
A problem that the company faced back in 2011 was the presence of mold infections at the manufacturing site, which was called out by the FDA. Merck, the other manufacturer of the vaccine, tried to fill in, but could not keep up with the demand. The next year will bring challenges for both providers and patients diagnosed with bladder cancer.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity
October 16th 2024Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.
Read More
